Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.
Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.
A recent study found that providing opioid use disorder treatment was associated with a high hep C cure rate and less drug use.
There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.
Treatment for hep C has improved greatly over the past decades, with medications that treat more than one virus strain at the same time.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
The drug can quickly reverse opioid-driven overdoses.
Past research has found that proton pump inhibitors and histamine H2 agonists are associated with lower levels of certain hep C drugs.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
These drugs are approved to treat all six major genotypes of hepatitis C.
This from a real-world analysis of people treated for hep C in the United States.
The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.
The subscription-based model is the first of its kind.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.